Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

88%

7 of 8 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 2

3(37.5%)

Phase 3

1(12.5%)

8Total

Phase 1(4)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04830800Phase 1Completed

A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)

Role: lead

NCT05940194Phase 2Completed

NDV-HXP-S Vaccine Clinical Trial (COVIVAC)

Role: lead

NCT04695717Phase 3Completed

This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam

Role: collaborator

NCT03095599Phase 2Completed

Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3

Role: lead

NCT02612909Phase 2Completed

A Safety and Immunogenicity Study of IVACFLU-A/H5N1

Role: lead

NCT02171819Phase 1Completed

Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

Role: lead

NCT01507779Phase 1Completed

Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine

Role: collaborator

NCT02598089Phase 1Completed

Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)

Role: lead

All 8 trials loaded